49 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
investments, that, paired with our enhanced deal skillset and expanded team, are expected to add robust programs and diversity to our product pipeline … in FSGS; the timing of clinical and regulatory events of Ligand’s partners; the expansion and diversity of Ligand’s portfolio; and guidance regarding
425
EX-99.1
57kg2w0ie95z0yo8x9a
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
4u92n8l7
21 Jun 22
Regulation FD Disclosure
6:19am
425
EX-99.2
hi9r8qtuvijcip
23 Mar 22
Business combination disclosure
5:29pm
425
EX-99.3
d15g83qea cj0h8o6p9
23 Mar 22
Business combination disclosure
5:29pm
8-K
EX-99.3
gikg2yanu
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.2
h3rui c0vqsd58ppm1t
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.1
bszbj
20 Oct 20
Results of Operations and Financial Condition
10:52am
8-K
h9acwxj 9xg
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
DEFA14A
hg6fxetl
4 Jun 19
Additional proxy soliciting materials
5:07pm